Adimab Discovers Sustainable Profitability Through GSK, Biogen Deals

The antibody engineering company Adimab LLC has signed two non-exclusive deals that should put the small biotech firmly in the black. The deals with GSK and Biogen, announced July 26, are Adimab’s first in which it transfers its technology for broad use by partners.